Printer Friendly

CELLPRO COMPLETES PATIENT ENROLLMENT FOR PHASE III LICENSING TRIAL OF CEPRATE SC STEM CELL SEPARATION SYSTEM

 SEATTLE, May 25 /PRNewswire/ -- CellPro Inc. (NASDAQ: CPRO) today announced that it has completed patient enrollment for the Phase III licensing trial of its CEPRATE(TM) SC Stem Cell Concentration System in autologous bone marrow transplantation to treat patients with breast cancer. The trial began in June 1992 and enrolled a total of 94 patients.
 The Phase III trial is a randomized, multicenter trial designed to demonstrate that stem cells purified from bone marrow with the CEPRATE SC System engraft equally as well as whole bone marrow and show a reduction in infusional toxicity. One half of the patients entered into the trial underwent a standard bone marrow transplantation, while the other half received a bone marrow transplant using marrow stem cells purified with the CEPRATE System. Stem cells are the "mother cells" in the bone marrow that are responsible for producing all blood and immune system cells. Trial sites were Emory University, the University of Colorado, the University of Pittsburgh, the University of Texas, M.D. Anderson Cancer Center and the University of Texas at San Antonio.
 "Timely completion of this Phase III trial is an important milestone in the clinical evaluation and eventual commercialization of the CEPRATE SC System," said Ronald J. Berenson, M.D., vice president of biological research and medical affairs for CellPro. "We are on our schedule to apply for marketing approval from the Food and Drug Administration."
 The CEPRATE SC Stem Cell Concentration System is a multi-component system that rapidly separates stem cells in a unique continuous-flow process. The CEPRATE SC System is also in trials for use in allogeneic (donor) bone marrow transplantation, as an adjunct to high dose chemotherapy and for purifying stem cells from the peripheral blood as a noninvasive alternative to bone marrow transplantation in the treatment of cancers. The system is also being used in several gene therapy trials for treating cancers and genetic disorders. CellPro technology is also being used to develop noninvasive alternatives to amniocentesis and chorionic villus sampling in genetic testing.
 Located in Bothell, Wash., CellPro Inc. is a biotechnology company specializing in the development, manufacturing and marketing of proprietary, continuous-flow, cell-selection systems for use in a variety of therapeutic, diagnostic and research applications.
 -0- 5/25/93
 /CONTACT: Lee M. Parker of CellPro, 206-485-7644/
 (CPRO)


CO: CellPro Inc. ST: Washington IN: MTC SU:

LM-GT -- SE003 -- 1985 05/25/93 08:16 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 25, 1993
Words:397
Previous Article:FLUKE COMPLETES ACQUISITION OF PHILIPS' TEST AND MEASUREMENT BUSINESS
Next Article:RENO AIR SIGNS AGREEMENT WITH AMERICAN
Topics:


Related Articles
CELLPRO TO PLAY KEY ROLE IN GENE THERAPY TRIAL FOR OVARIAN CANCER AT M.D. ANDERSON USING MULTIDRUG RESISTANCE GENE
CELLPRO SYSTEM TO BE USED IN GENE THERAPY TRIALS FOR GAUCHER'S DISEASE
CELL GENESYS AND CELLPRO COLLABORATE ON ANTI-HIV T CELLS FOR AIDS
CELL GENESYS ISSUED BROAD PATENT FOR UNIVERSAL RECEPTOR CELL TECHNOLOGY
Baxter: Federal Jury Awards $2.3 Million to Johns Hopkins, Baxter and Becton Dickinson in Patent Infringement Case
CellPro: Baxter Injunction Terms Hit Cancer Patients Hardest

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters